Trial · NCT06730672
An Exploratory Study on the Failure of Immunotherapy With Vorolanib Combined With Everolimus
NCT06730672, Phase 2, Recruiting, Sun Yat-sen University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. An Exploratory Study on the Failure of Immunotherapy With Vorolanib Combined With Everolimus. Trials, record NCT06730672. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06730672
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Exploratory Study on the Failure of Immunotherapy With Vorolanib Combined With Everolimus
- NCT number
- NCT06730672
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 80 participants, estimated
- Lead sponsor
- Sun Yat-sen University
- Conditions
- Renal Cell Carcinoma Stage I
- Interventions
- Vorolanib combined with Everolimus Formation
- First posted
- 2024-12-12
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival | From date of initiate treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months until disease progression or death | The definition of Progression-free survival（PFS） is the time from the date of first dose until the first observation of disease progression (PD) (as determined by radiographic assessment) or death (whichever occurs first). |
| Secondary | Overall survival | From date of initiate treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months until disease progression or death | Overall survival（OS） was defined as the time from the date of first dose to the date of death from any cause. |
| Secondary | Objective response rate | From date of initiate treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months until disease progression or death | The Objective response rate（ORR） was defined as the proportion of patients with a best overall response of complete or partial response. |
| Secondary | Disease control rate | From date of initiate treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months until disease progression or death | Disease control rate（DCR）was defined the proportion of patients with complete response, partial response, and stable disease. |
| Secondary | Duration of response | From date of initiate treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months until disease progression or death | Duration of response (DOR)defined as the time from first documented response, PR or CR, to progressive disease \[PD\] or death; patients who neither progressed nor died were censored on the date of their last radiographic tumor assessment. |
| Secondary | Dynamic changes in ctDNA levels and alterations in the ctDNA mutation profile | In this study, a maximum of six blood samples were collected for ctDNA testing, specifically before treatment, and after drug treatment at 2 months, 4 months, 6 months, 8 months, and at the time of PD (progressive disease) occurrence up to 36 months | In this study, blood samples were collected for ctDNA testing. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06730672
GET https://conductscience.org/api/trials/v1/NCT06730672/registered